Mission Therapeutics announces publication in Nature Reviews Drug Discovery of article highlighting how neurodegenerative diseases can be tackled by enhancing mitophagy
- Review article in high impact journal outlines the evidence that neurodegenerative diseases –including Parkinson’s, Alzheimer’s, ALS and Huntington’s – can be addressed by boosting mitophagy, the quality control system cells use to remove dysfunctional mitochondria
- Strong evidence has emerged that deficient mitophagy is an underlying cause of neurodegenerative disease
- Momentum is building, with the first selective mitophagy enhancers aimed at modifying the course of neurodegenerative diseases entering clinical trials in the last 12 months
CAMBRIDGE, UK, 15 January 2025 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a review article titled Targeting mitophagy in neurodegenerative diseases in the journal Nature Reviews Drug Discovery. The peer-reviewed article can be viewed here.
